1. Market Research
  2. > Biotechnology
  3. > Medical Biotechnology Market Trends
Commercialisation of Biologics: Benchmarking leading players

Commercialisation of Biologics: Benchmarking leading players

  • October 2017
  • ID: 5214609
  • Format: PDF
  • By Firstword Pharma


Table of Contents

Commercialisation of Biologics: Benchmarking Leading Players
It’s clear that the rapidly growing biologics sector holds a wealth of promise. The significant opportunities resulting from breaking new ground are obviously attractive, but just how effective have biologics manufacturers been so far in commercialising these innovative drugs? How have key players navigated stumbling blocks such as inconsistent patient and physician acceptance and growing payer discomfort with hefty price tags? Which companies are achieving success – and how are they getting there?

Discover on this page…
• The executive summary, taken directly from the report, presents key findings from the research
• Research objectives and methodologies employed to produce the report
• Detailed report contents
• Key themes covered in the report
• What you will learn from the report

1. Executive Summary
Biologics are considered to be at the cutting edge of medical science and have made significant inroads in controlling and sometimes curing previously difficult to treat long-term chronic conditions. Their use has become more prevalent in recent years and they represent a rapidly growing sector, contributing $232 billion in revenues to the global pharmaceutical industry in 2016.
• Nonetheless, there are numerous challenges to the commercialisation of biologics. They are complex and costly to develop and manufacture, contributing to higher pricing than small molecules. In addition, more competing biological therapies are entering the market, contributing to spiralling costs to healthcare systems that are working with increasingly leaner budgets. Payers are therefore operating with greater scrutiny in seeking the value of these innovative therapies; the onus is on pharmaceutical companies to demonstrate the benefits relative to the costs.
• The aim of this report is to help company’s intent on entering the biologics sector navigate such challenges and achieve commercial success. To this end, eight leading pharmaceutical players that have successfully launched a biologic were benchmarked on how they approached the commercialisation of their products.
• The various elements of the commercialisation of biologics were explored, including the internal and external barriers faced by manufacturers in getting their products to market, team roles and core competencies, launch and market access strategies, stakeholder engagement and measuring commercialisation success..

Eight key factors for successful commercialisation were identified and are discussed in depth within the report.
• A ‘think global, act local’ approach to product launches ’Beyond the pill’ market access strategies
• ’Beyond the pill’ market access strategies
• Specialised key performance indicators
• Flexible pricing/reimbursement models
• Market access, health economics and medical affairs teams
• Synergistic partnerships with other organisations such as academic institutions, contract research organisations, and other pharmaceutical companies
• Emphasis on data transparency and real-world evidence
• Use of written publications, digital technologies and personal interaction to engage stakeholders
• While some of these factors may seem obvious, the valuable information is in how the eight benchmarked companies approached them to achieve success. Comparative tables are used to highlight the commonalities and differences between benchmarked companies in terms of pricing strategies, launch and market access strategies, and stakeholder engagement strategies.
• These eight key success factors demonstrate that developing innovative biologics that effectively treat diseases is not enough to achieve successful commercialisation. Pharma companies also need to position themselves as healthcare solution providers that address the problems faced by patients, physicians, payers and healthcare systems. Future players in the biologics space need to create a positive environment for innovation and collaboration, involve all key stakeholders throughout the development process, provide solutions to the challenges faced by healthcare systems, place more emphasis on generating real-world evidence and develop relevant key performance indicators to monitor performance.

2. Research Methodology and Objectives
Designed to give existing and new market entrants an insight into the nuances and strategies for commercialising biologics, this report outlines the success factors, provides a benchmark and offers recommendations. Expert views are backed up with case studies and data on pharma’s biologic drug success stories so far.
Analysis is based on detailed interviews carried out during July and August 2017 with 8 commercially focused biologics professionals within the pharmaceutical industry.

Durgaprasad Annavajjula, Sr. Vice President, Stelis Biopharma Pvt Ltd.

Jennifer Butler, Chief Commercial Officer, Tessa Therapeutics Pte Ltd.

Guillaume Clement, Executive Vice President Europe, Australia, Canada, LEO Pharma A/S

Kirsten Detrick, Managing Director - Austria, Takeda Pharmaceuticals GmbH, and former Vice President, Global Commercial, Therapeutic Area Commercial Lead, Gastroenterology, Takeda Pharmaceuticals USA

Frank Dolan, National Sales Director, ACADIA Pharmaceuticals Inc.

Kasia Hein-Peters, Vaxelis Marketing Head, Sanofi Pasteur

Teri Lawver, Global Vice President, Immunology, Janssen Pharmaceutical Companies of Johnson & Johnson

Anonymous expert, Former executive at Takeda Pharmaceuticals and Pfizer

Key questions explored in this report include
• What key differences should be recognised when launching biologics versus other products?
• What internal and external barriers are hampering the commercialisation of biologics?
• Which key internal roles are making a difference, and which elements could be outsourced?
• What are the various pricing strategies currently used?
• How are successful companies identifying and meeting stakeholder needs?
• How are global and local biologic launches handled differently to maximise effectiveness?
• What KPIs should be used to measure activity effectiveness?
• Which innovative ideas for commercialisation should new market entrants be considering?

4. More reasons to buy this report
A host of new market entrants are either poised to parachute into the centre of the biologics arena or already taking their first steps towards success. The steady influx of players is turning up the heat, not only for competing drug companies, but also for payers, physicians and patients who all want to reap the potential benefits, but have concerns that need addressing too. Drug companies that simply dive in with their new biologic might be unpleasantly surprised. Why? Because a ‘build it and they will come’ approach won’t work for a host of reasons. Successful commercialisation of a biologic is not business as usual – far from it.

This report will enable you to…
• Review the key factors involved in commercialisation of biologics at a global and local level as well as how to measure success.
• Prepare your team for the obstacles and challenges ahead, and make plans on how to overcome internal and external barriers.
• Find out how to organise your resources in order to achieve optimum impact across R&D, market access, medical affairs and key accounts.
• Build a stakeholder strategy pertinent to biologics which addresses key needs and ensures a targeted approach.
• See what success looks like and how it has been achieved for the top ranked biologic market participants.
• Benchmark your plans and strategies against the best and see how your approach compares.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
House Dust Mite Allergy - Pipeline Review, H1 2020

House Dust Mite Allergy - Pipeline Review, H1 2020

  • $ 2000
  • January 2020

House Dust Mite Allergy - Pipeline Review, H1 2020SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide House Dust Mite Allergy - Pipeline Review, H1 2020, provides an overview of the ...

Macrophage Migration Inhibitory Factor - Pipeline Review, H2 2019

Macrophage Migration Inhibitory Factor - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

Macrophage Migration Inhibitory Factor - Pipeline Review, H2 2019SummaryMacrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase o ...

Highs and Lows of Stem Cell Therapies: Off- The-Shelf Solutions

Highs and Lows of Stem Cell Therapies: Off- The-Shelf Solutions

  • $ 3950
  • December 2019

Report Includes:- An overview of recent advances in stem cell therapies and coverage of potential stem cells used for regenerative advanced therapies- Discussion on role of genomic and epigenomics manipulations ...


Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on